China
Africa
Explore chapters and articles related to this topic
Obesity
Published in Andrew Stevens, James Raftery, Jonathan Mant, Sue Simpson, Health Care Needs Assessment, 2018
John Garrow, Carolyn Summerbell
Other SSRIs (e.g. fluoxetine, femoxetine or sertraline) had no apparent added effect on weight loss or maintenance or any of the reported risk factors. At 12 months the added effect of SSRIs on weight reduction was associated with an overall WMD weight change of -0.33 kg (95% CI −1.49 to 0.82 kg).
Medical Management of Obesity Associated with Mood Disorders
Published in Susan L. McElroy, David B. Allison, George A. Bray, Obesity and Mental Disorders, 2006
Susan L. McElroy, Renu Kotwal, Paul E. Keck
Regarding other SSRIs in the treatment of obesity, a 16-week trial of femoxetine 600 mg/day in 73 obese patients in general practice showed similar weight loss in patients receiving active drug (median = 8.3 kg) compared with patients receiving placebo (median = 6.2 kg) (214). However, there was a trend for greater weight loss in those patients with obesity for more than 20 years and in those patients receiving previous anorectic treatments. Two studies of citalopram in obesity were negative (215,216). The first was a 12-week trial of 60 mg/day in 65 patients with severe obesity and the second was a 6-month, cross-over trial of 40 mg/day in 16 men with abdominal obesity. Two short-term studies (12 and 13 weeks, respectively) of fluvoxamine in patients with obesity were also negative but both studies were small (40 subjects in each) (217,218). Nonetheless, in one study, subjects receiving fluvoxamine achieved a greater mean weight loss than those receiving placebo (217). In an uncontrolled comparison of two consecutive series of obese patients (BMI ≥ 30) with similar characteristics receiving six months of cognitive behavioral therapy (CBT) for weight loss, patients receiving sertraline 150 mg/day plus CBT (N = 65) lost significantly more weight than patients receiving CBT alone (N = 60; 6.5% vs. 3.0 %; p < 0.01) (219). In the only controlled study of sertraline in obesity, sertraline 200 mg/day was not different from placebo in preventing regain of weight in 30 obese women who completed 54 weeks of relapse prevention training following a very low calorie diet, even though active drug was initially associated with greater weight loss (220).
The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression
Published in Expert Opinion on Pharmacotherapy, 2021
Mina Borran, Simin Dashti-Khavidaki, Hossein Khalili
Scant data show the direct effect of antidepressants on the reduction of HIV replication [58,59]. In-vitro evaluation of the effects of amitriptyline, nortriptyline, femoxetine, and paroxetine has shown a promising effect in decreasing viral replication [59]. Tsai et al. reported 2.03 greater odds in viral suppression following depression treatment with antidepressants in homeless HIV patients (CD4 < 350 cells/mm3) on ART. After adjustment for confounding factors, antidepressants revealed 1.58 greater odds in viral suppression. The authors interpreted ART adherence as an explanation for this effect. They also considered the biological effect of antidepressants that could not be evaluated in that study [58].